Table of Contents

• 1.   Market Introduction
  •   1. Objectives of the Study
      2. Market Definition
      3. Market Scope
       3.1 . Years Considered for the Study
       3.2 . Market Covered
      4. Currency
      5. Limitations
      6. Stakeholders
    
• 2.   Research Methodology
  •   1. Research Data
       1.1 . Secondary Data
        1.1.1 . Key Data from Secondary Sources
       1.2 . Primary Data
        1.2.1. Key Data from Primary Sources
      2. Market Size Estimation
      3. Market Breakdown and Data Triangulation
      4. Assumptions for the Study
    
• 3.   Executive Summary
  •   1. Market Outlook
      2. Segment Outlook
      3. Competitive Insights
    
• 4.   Asia-Pacific Oncology Molecular Diagnostics Market Variables, Trends and Scope

  •   1. Market Lineage Outlook
      2. Penetration and Growth Prospect Mapping
      3. Industry Value Chain Analysis
      4. Cost Analysis Breakdown
      5. Technology Overview
      6. Regulatory Framework
       6.1. Reimbursement Framework
       6.2. Standards and Compliances

• 5.   Market Overview
  •   1. Market Dynamics
       1.1. Market Driver Analysis
        1.1.1. Increasing focus of Asia-Pacific Oncology Molecular Diagnostics Companies on Brand Protection
        1.1.2. Untapped Opportunities in Emerging Regions
       1.2. Market Restraint Analysis
        1.2.1. High Cost Associated with Implementation of Predictive Analysis
       1.3. Industry Challenges
        1.3.1. Presence of Ambiguous Regulatory Framework
    
• 6.   Asia-Pacific Oncology Molecular Diagnostics Market Analysis Tools
  •   1. Industry Analysis - Porter’s
       1.1. Supplier Power
       1.2. Buyer Power
       1.3. Substitution Threat
       1.4. Threat from New Entrants
       1.5. Competitive Rivalry
      2. Pestel Analysis
       2.1. Political Landscape
       2.2. Environmental Landscape
       2.3. Social Landscape
       2.4. Technology Landscape
       2.5. Legal Landscape
      3. Major Deals And Strategic Alliances Analysis
       3.1. Joint Ventures
       3.2. Mergers and Acquisitions
       3.3. Licensing and Partnership
       3.4. Technology Collaborations
       3.5. Strategic Divestments
      4. Market Entry Strategies
      5. Case Studies
    
• 7.   Asia-Pacific Oncology Molecular Diagnostics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Hematological Cancer
      5. Others

• 8.   Asia-Pacific Oncology Molecular Diagnostics Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Hospitals
      2. Reference Laboratories
      3. Others

• 9.   Asia-Pacific Oncology Molecular Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. Japan
       2.2. China
       2.3. India
       2.4. Australia and New Zealand
       2.5. ASEAN
       2.6. Rest of Asia Pacific
      3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

• 10.   Market Share Analysis and Competitive Landscape

  •   1. Asia Pacific Landscape - Key Players, Revenue and Presence
      2. Asia Pacific Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
      3. Asia Pacific Emerging Companies
      4. Asia Pacific - Market Share Analysis and Key Regional Players
      5. Asia Pacific Key Player - Growth Matrix

• 11.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

  •   1. F. Hoffmann-La Roche AG
       1.1. Company Overview
       1.2. Product Portfolio
       1.3. SWOT Analysis
       1.4. Financial Overview
       1.5. Strategic Overview
      2. BioMérieux SA
       2.1. Company Overview
       2.2. Product Portfolio
       2.3. SWOT Analysis
       2.4. Financial Overview
       2.5. Strategic Overview
      3. Abbott Laboratories
       3.1. Company Overview
       3.2. Product Portfolio
       3.3. SWOT Analysis
       3.4. Financial Overview
       3.5. Strategic Overview
      4. Qiagen N.V.
       4.1. Company Overview
       4.2. Product Portfolio
       4.3. SWOT Analysis
       4.4. Financial Overview
       4.5. Strategic Overview
      5. Illumina
       5.1. Company Overview
       5.2. Product Portfolio
       5.3. SWOT Analysis
       5.4. Financial Overview
       5.5. Strategic Overview
      6. Danaher Corporation
       6.1. Company Overview
       6.2. Product Portfolio
       6.3. SWOT Analysis
       6.4. Financial Overview
       6.5. Strategic Overview
      7. Agilent Technologies Inc
       7.1. Company Overview
       7.2. Product Portfolio
       7.3. SWOT Analysis
       7.4. Financial Overview
       7.5. Strategic Overview
      8. Sysmex Corporation
       8.1. Company Overview
       8.2. Product Portfolio
       8.3. SWOT Analysis
       8.4. Financial Overview
       8.5. Strategic Overview
      9. Siemens Healthcare
       9.1. Company Overview
       9.2. Product Portfolio
       9.3. SWOT Analysis
       9.4. Financial Overview
       9.5. Strategic Overview
      10. Diasorin SPA
       10.1. Company Overview
       10.2. Product Portfolio
       10.3. SWOT Analysis
       10.4. Financial Overview
       10.5. Strategic Overview

• 12.   Pre and Post COVID-19 Impact
  •   1. Positive influence on the healthcare industry
      2. The financial disruption of the manufacturing sector
      3. Impact of COVID-19 on emerging companies
      4. Significant mandates in the healthcare regulations initiated by administrations
      5. The overall economic slowdown of the developing and developed nations
    
• 13.   FutureWise SME Key Takeaway Points for Client